Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
LB PHARMACEUTICALS INC issued pre-funded warrants to purchase up to 1,417,107 shares of warrant to institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners) for $21.1699 per pre-funded warrant.
- Security
- warrant
- Shares
- pre-funded warrants to purchase up to 1,417,107 shares
- Purchaser
- institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners)
- Consideration
- $21.1699 per pre-funded warrant
Exact text from the filing
to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
LB PHARMACEUTICALS INC issued 3,306,571 shares of common stock to institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners) for $21.17 per share.
- Security
- common stock
- Shares
- 3,306,571 shares
- Purchaser
- institutional investors (including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners)
- Consideration
- $21.17 per share
Exact text from the filing
to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
LB PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain investors valued at approximately $100.0 million (effective 2026-02-04).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain investors
- Value
- approximately $100.0 million
- Effective
- 2026-02-04
Exact text from the filing
On February 4, 2026, LB Pharmaceuticals Inc (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”) pursuant to which the Company, in a private placement (the “Private Placement”), agreed to issue and sell to the Investors an aggregate of (i) 3,306,571 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,417,107 shares of Common Stock
View on SEC.gov